NASDAQ:OBLN - Obalon Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.53 +0.07 (+2.85 %)
(As of 06/18/2018 04:00 PM ET)
Previous Close$2.46
Today's Range$2.40 - $2.54
52-Week Range$2.09 - $11.54
Volume706,870 shs
Average Volume184,957 shs
Market Capitalization$43.23 million
P/E Ratio-1.20
Dividend YieldN/A
Beta-2.67

About Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics logoObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBLN
CUSIPN/A
Phone760-795-6558

Debt

Debt-to-Equity Ratio0.29
Current Ratio4.29
Quick Ratio4.09

Price-To-Earnings

Trailing P/E Ratio-1.20
Forward P/E Ratio-1.16
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.91 million
Price / Sales4.49
Cash FlowN/A
Price / CashN/A
Book Value$1.54 per share
Price / Book1.64

Profitability

EPS (Most Recent Fiscal Year)($2.08)
Net Income$-34,760,000.00
Net Margins-399.94%
Return on Equity-102.17%
Return on Assets-71.95%

Miscellaneous

Employees113
Outstanding Shares17,570,000

Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics Inc (NASDAQ:OBLN) announced its quarterly earnings data on Monday, March, 5th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.12. The company had revenue of $3.69 million for the quarter, compared to the consensus estimate of $3.88 million. Obalon Therapeutics had a negative net margin of 399.94% and a negative return on equity of 102.17%. View Obalon Therapeutics' Earnings History.

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Obalon Therapeutics.

What price target have analysts set for OBLN?

5 equities research analysts have issued 1-year target prices for Obalon Therapeutics' stock. Their predictions range from $4.00 to $16.00. On average, they expect Obalon Therapeutics' share price to reach $9.25 in the next twelve months. View Analyst Ratings for Obalon Therapeutics.

What are Wall Street analysts saying about Obalon Therapeutics stock?

Here are some recent quotes from research analysts about Obalon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (5/16/2018)
  • 2. Northland Securities analysts commented, "We have reached out to management, but have not heard back yet. As we have said multiple times in our notes, we are persona non grata with the company, hence are not hopeful that we can have adequate answers to our questions, which are: What specifically is the allegation? Is it about channel stuffing? Is it about revenue recognition? As highlighted in our Dec 6, 2017 research note, we had questions about Obalon’s revenue recognition criteria, and how the accounting for deliverables was being done. A key question for us is…who knew what & when? Is there any truth to the whistleblower allegations, whatever they may be? As a reminder, Obalon’s new marketing program was implemented at start of Q4-17." (1/23/2018)

Who are some of Obalon Therapeutics' key competitors?

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the folowing people:
  • Mr. Andrew P. Rasdal, Pres, CEO & Director (Age 60)
  • Mr. William John Plovanic CFA, CFO & Sec. (Age 49)
  • Mr. Mark C. Brister, Chief Technology Officer (Age 56)
  • Dr. Kelly Huang Ph.D., Chief Operating Officer (Age 49)
  • Ms. Nooshin Hussainy, VP of Fin. & Principal Accounting Officer (Age 60)

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Has Obalon Therapeutics been receiving favorable news coverage?

News articles about OBLN stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Obalon Therapeutics earned a media sentiment score of 0.08 on Accern's scale. They also assigned news headlines about the company an impact score of 47.03 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Obalon Therapeutics' major shareholders?

Obalon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Tamarack Advisers LP (2.42%), Massachusetts Financial Services Co. MA (1.78%), C WorldWide Group Holding A S (1.41%), Tiverton Asset Management LLC (0.43%) and Granite Investment Partners LLC (0.27%). Company insiders that own Obalon Therapeutics stock include Kim P Kamdar, Matthew Norwood, Neil Drake and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.

Which major investors are selling Obalon Therapeutics stock?

OBLN stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Tamarack Advisers LP, Granite Investment Partners LLC, C WorldWide Group Holding A S and Tiverton Asset Management LLC. View Insider Buying and Selling for Obalon Therapeutics.

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $2.53.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $43.23 million and generates $9.91 million in revenue each year. The company earns $-34,760,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Obalon Therapeutics employs 113 workers across the globe.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]


MarketBeat Community Rating for Obalon Therapeutics (OBLN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.